Tech Company Financing Transactions

Encoded Therapeutics Funding Round

Encoded Therapeutics, based in San Francisco, raised $104 million from Alexandria Venture Investments, Altitude Life Science Ventures and Arch Venture Partners.

Transaction Overview

Announced On
6/27/2019
Transaction Type
Venture Equity
Amount
$104,000,000
Round
Series C
Investors

Alexandria Venture Investments

Altitude Life Science Ventures

Arch Venture Partners

Boxer Capital

Illumina Ventures

Matrix Capital Management

Menlo Ventures

RTW Investments

Venrock (Bryan Roberts)

Proceeds Purpose
Encoded will use the funds to advance its lead program in Dravet Syndrome and its preclinical pipeline, as well as to leverage its platform to develop new therapeutics to treat severe genetic disorders.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
341 Oyster Point Blvd.
San Francisco, CA 94080
USA
Email Address
Overview
Encoded Therapeutics, Inc., is a biotechnology company developing precision gene therapies for a broad range of severe genetic disorders. Our mission is to realize the potential of genomics-driven precision medicine by overcoming key limitations of viral gene therapy.
Profile
Encoded Therapeutics LinkedIn Company Profile
Social Media
Encoded Therapeutics Company Twitter Account
Company News
Encoded Therapeutics News
Facebook
Encoded Therapeutics on Facebook
YouTube
Encoded Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chairman
Sean Nolan
  Sean Nolan LinkedIn Profile  Sean Nolan Twitter Account  Sean Nolan News  Sean Nolan on Facebook
Chief Executive Officer
Kartik Ramamoorthi
  Kartik Ramamoorthi LinkedIn Profile  Kartik Ramamoorthi Twitter Account  Kartik Ramamoorthi News  Kartik Ramamoorthi on Facebook
Chief Medical Officer
Salvador Rico
  Salvador Rico LinkedIn Profile  Salvador Rico Twitter Account  Salvador Rico News  Salvador Rico on Facebook
Chief Operating Officer
David Oberkofler
  David Oberkofler LinkedIn Profile  David Oberkofler Twitter Account  David Oberkofler News  David Oberkofler on Facebook
Chief Scientific Officer
Stephanie Tagliatela
  Stephanie Tagliatela LinkedIn Profile  Stephanie Tagliatela Twitter Account  Stephanie Tagliatela News  Stephanie Tagliatela on Facebook
Chief Technical Officer
Martin Moorhead
  Martin Moorhead LinkedIn Profile  Martin Moorhead Twitter Account  Martin Moorhead News  Martin Moorhead on Facebook
VP - Bus. Development
David McNinch
  David McNinch LinkedIn Profile  David McNinch Twitter Account  David McNinch News  David McNinch on Facebook
VP - Human Resources
Monique Bobadilla
  Monique Bobadilla LinkedIn Profile  Monique Bobadilla Twitter Account  Monique Bobadilla News  Monique Bobadilla on Facebook
VP - Manufacturing
Andrew Stober
  Andrew Stober LinkedIn Profile  Andrew Stober Twitter Account  Andrew Stober News  Andrew Stober on Facebook
VP - Regulatory Affairs
Nancy Boman
  Nancy Boman LinkedIn Profile  Nancy Boman Twitter Account  Nancy Boman News  Nancy Boman on Facebook


 

 

Browse more venture capital transactions:

Prev: 6/27/2019: AUrate venture capital transaction
Next: 6/27/2019: PHLUR venture capital transaction

 

Share this article

 


News on VC Transactions

We report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary